0000000000962786

AUTHOR

Laura Ansone

showing 4 related works from this author

Alterations in blood sera metabolome and blood transcriptome in hospitalized COVID-19 patients

2021

COVID-19 pandēmija turpina būt lielākais globālais drauds sabiedrības veselībai, sasniedzot ne tikai apjomīgus infekcijas gadījumu skaitus, bet arī salīdzinoši augstu mirstību starp tiem (~2%). COVID-19 raksturīga heterogēna slimības gaita un šobrīd nav atrasti medikamenti, kas novērš smaga un kritiska stāvokļa iestāšanos. Lai noskaidrotu kādi mehānismi iesaistīti stacionētu COVID-19 pacientu patoģenēzē, tika veikta mērķēta metaboloma un transkriptoma analīze divos laika punktos: pacientam iestājoties slimnīcā un aptuveni 30 dienas vēlāk, tādejādi salīdzinot akūtās fāzes paraugus pret atveseļošanās fāzi. Rezultāti liecina par spēcīgām izmaiņām vairākos metabolajos un imūnsistēmas signālceļo…

transkriptomsSARS-CoV-2COVID-19Bioloģijametaboloms
researchProduct

First Report on the Latvian SARS-CoV-2 Isolate Genetic Diversity

2021

Remaining a major healthcare concern with nearly 29 million confirmed cases worldwide at the time of writing, novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused more than 920 thousand deaths since its outbreak in China, December 2019. First case of a person testing positive for SARS-CoV-2 infection within the territory of the Republic of Latvia was registered on 2nd of March 2020, 9 days prior to the pandemic declaration by WHO. Since then, more than 277,000 tests were carried out confirming a total of 1,464 cases of coronavirus disease 2019 (COVID-19) in the country as of 12th of September 2020. Rapidly reacting to the spread of the infection, an ongoing sequenci…

0301 basic medicineHCoV-19Coronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)medicine.disease_cause03 medical and health sciences0302 clinical medicinePandemicmedicineChinaOriginal ResearchCoronavirusGenetic diversitylcsh:R5-920SARS-CoV-2LatvianOutbreakCOVID-19General Medicinegenetic diversityVirologyLatvialanguage.human_language030104 developmental biologyGeography2019-nCoVlanguageMedicinenext-generation sequencingSevere acute respiratory syndrome coronaviruslcsh:Medicine (General)030217 neurology & neurosurgeryFrontiers in Medicine
researchProduct

Whole-blood transcriptome profiling reveals signatures of metformin and its therapeutic response

2020

Metformin, a biguanide agent, is the first-line treatment for type 2 diabetes mellitus due to its glucose-lowering effect. Despite its wide application in the treatment of multiple health conditions, the glycemic response to metformin is highly variable, emphasizing the need for reliable biomarkers. We chose the RNA-Seq-based comparative transcriptomics approach to evaluate the systemic effect of metformin and highlight potential predictive biomarkers of metformin response in drug-naive volunteers with type 2 diabetes in vivo. The longitudinal blood-derived transcriptome analysis revealed metformin-induced differential expression of novel and previously described genes involved in cholester…

0301 basic medicineMaleendocrine system diseasesMolecular biologyGene ExpressionType 2 diabetesPharmacologyBiochemistryTranscriptome0302 clinical medicineEndocrinologyMedical ConditionsSequencing techniquesGastrointestinal CancersBreast TumorsMedicine and Health SciencesHomeostasisEnergy-Producing OrganellesWhole bloodMultidisciplinarySmall nuclear RNABiguanideQRRNA sequencingGenomicsMiddle AgedMetforminMetforminMitochondriaType 2 DiabetesNucleic acidsCholesterolSmall nucleolar RNAOncology030220 oncology & carcinogenesisMedicineFemaleCellular Structures and OrganellesTranscriptome Analysismedicine.drugResearch Articlemedicine.drug_classEndocrine DisordersScienceGastroenterology and HepatologyBioenergetics03 medical and health sciencesBreast CancermedicineGeneticsDiabetes MellitusHumansNon-coding RNAGlycemicAgedbusiness.industryGene Expression ProfilingType 2 Diabetes Mellitusnutritional and metabolic diseasesBiology and Life SciencesComputational BiologyCancers and NeoplasmsCell Biologymedicine.diseaseGenome AnalysisGene regulationGene expression profilingResearch and analysis methods030104 developmental biologyMolecular biology techniquesMetabolic DisordersRNAbusinessBlood Chemical AnalysisPLoS ONE
researchProduct

Metformīna ierosinātas izmaiņas gēnu ekspresijas profilos otrā tipa cukura diabēta pacientos

2019

Metformīns ir pirmās izvēles medikaments 2. tipa cukura diabēta ārstēšanā, tā terapeitiskais efekts ir pierādīts ļaundabīgo audzēju un neirodeģeneratīvu slimību ārstēšanā. Metformīnam ir raksturīga variabla efektivitāte, turklāt medikamenta darbības mehānisms joprojām nav skaidrs. Pētījuma ietvaros tika veikta uz nākamās paaudzes sekvencēšanu balstīta asins šūnu transkriptoma analīze 17 eiropeiskas izcelsmes 2. tipa cukura diabēta pacientiem pirms metformīna terapijas uzsākšanas un pēc trīs mēnešus ilgas metformīna lietošanas. Rezultāti liecina, ka metformīns statistiski nozīmīgi izmaina 28 gēnu ekspresijas līmeni 2. tipa cukura diabēta pacientu asins šūnās, turklāt tā ietekme uz šūnu signā…

transkriptomsmetformīns2. tipa cukura diabētsBioloģijadiferenciāli ekspresēti gēni
researchProduct